Mastoferon

Therapeutic indications:

The drug is used for the treatment of cows suffering from subclinical and clinical (serous and catarrhal) mastitis during lactation.

Composition of the veterinary drug:

The drug is packed in plastic syringes (10 g). One syringe contains:

• recombinant bovine interferon 1 000 IU

Pharmacological activity:

The veterinary drug exhibits both antiviral and immunostimulatory activity. Recombinant bovine interferon, which is an active ingredient of the drug, acts as an inducer of bactericidal activity and lysozyme activity of blood serum, cellular and humoral immunity, has an anti-inflammatory effect and increases the body's resistance to DNA and RNA-containing viruses and pathogenic microorganisms.

The immunostimulatory activity of interferon reaches its maximum level after 12 hours and persists for the next 24-48 hours.

Dosage:

The drug is administered intracisternally into the affected part of the udder at a dose of 10 g (one syringe) twice a day with an interval of 8-14 hours (after morning and evening milking) for three days or until complete cure (no more than 12 days). The procedure for using the drug must be followed regardless of the milking regime (two or three times).

Before administering the drug, the contents of the diseased part of the udder are milked out, and the skin of the nipple is treated with an antiseptic (cleansing wipe) approved for these purposes. Then remove the cap from the tip of the syringe and insert it into the teat canal, squeezing the contents into the affected lobe of the udder. After that, remove the syringe, pinch the tip of the teat with fingers and massage the lobe of the udder from the bottom up.

The effectiveness of treatment of cows with mastitis is monitored by clinical examination of the mammary gland, examination of its secretion and a mastitis test 4–12 days after the start of treatment.

Precautions and adverse reactions:

Side effects and complications when using the drug in accordance with this instruction have not been observed.

Do not use of the drug in animals with increased individual sensitivity to the components of the drug.

No overdose symptoms in animals have been revealed.

The use of the drug does not exclude the use of antimicrobial, pathogenetic and symptomatic therapy, as well as recombinant bovine interferon.

No pecularities have been revealed after first use and cancellation of the drug.

If administration of the drug is missed, resume it in the recommended dose and the treatment scheme.

Withdrawal period:

Milk for human consumption from non-affected quarters may be taken without limitations. Milk for human consumption from drug-treated quarters may be taken only after the treatment course is completed and somatic cell count (SCC) is back to normal. During the period of treatment milk may be used as animal feed after boiling without limits. Animals may be slaughtered for human consumption without limitations.

In complex therapy with the use of additional treatment agents, milk and meat are used for human consumption in accordance with the time periods specified in the instructions for these agents.

Storage conditions:

Store in a dark place at a temperature of 2 °C to 25 °C. 

Shelf-life:

Shelf-life of the veterinary drug under appropriate storage conditions is 1 year from the date of manufacture.